# A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants

> **NCT05896683** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 72 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Lazertinib

## Key facts

- **NCT ID:** NCT05896683
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-30
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05896683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05896683, "A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05896683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*